Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 10 of 10 entries
View as:

Transplant-Related Mortality in Patients Undergoing a Peripheral Blood Stem Cell Transplantation or an Umbilical Cord Blood Transplantation

Phase: N/A Priority: Normal
NCT ID: NCT02188290 Org: User:
Start: 09/30/14 End: 06/30/15 Due: 06/30/16

Theralux Extracorporeal Photochemotherapy (ECP) in Patients With Extensive Chronic Graft Versus Host Disease (GvHD)

Phase: N/A Priority: Normal
NCT ID: NCT00248365 Org: User:
Start: 11/30/05 End: 08/31/07 Due: 08/31/08

Safety and Efficacy of Donor T-lymphocytes Depleted ex Vivo of Host Alloreactive T-cells (ATIR) in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor

Phase: N/A Priority: Normal
NCT ID: NCT01794299 Org: User:
Start: 03/31/13 End: 09/30/17 Due: 09/30/18

Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor

Phase: N/A Priority: Normal
NCT ID: NCT02500550 Org: User:
Start: 10/09/15 End: 12/17/18 Due: 12/17/19

Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor

Phase: N/A Priority: Normal
NCT ID: NCT00967343 Org: User:
Start: 08/31/09 End: 02/29/12 Due: 02/28/13

Off-the-shelf NK Cells (KDS-1000) as Immunotherapy for COVID-19

Phase: N/A Priority: Normal
NCT ID: NCT04797975 Org: User:
Start: 12/31/20 End: 04/30/21 Due: 04/30/22

Dose-ranging Study of a Single Administration of T-cell Add-back Depleted of Host Alloreactive Cells in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor

Phase: N/A Priority: Normal
NCT ID: NCT00993486 Org: User:
Start: 01/31/05 End: 04/30/13 Due: 04/30/14

NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS)

Phase: N/A Priority: Normal
NCT ID: NCT00248404 Org: User:
Start: 09/30/05 End: 12/12/07 Due: 12/12/08

Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)

Phase: N/A Priority: Normal
NCT ID: NCT04395092 Org: User:
Start: 11/13/20 End: 11/30/23 Due: 11/30/24

Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02999854 Org: User:
Start: 11/29/17 End: 12/17/21 Due: 12/17/22